TELA
TELA Bio, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Buy
+51/100
Last price
1.16
▲ 0.02 (1.75%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.16
Prev close
1.14
Day high
1.30
Day low
1.09
Volume
146.25K
Market cap
$49.21M
P/E (TTM)
—
52W range
0.50 – 1.60
Day trading desk
Gap from prior close
+1.75%
Prior close 1.14
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
1.16 – 1.16
Position in range
—
—
ATR (14D)
0.13
11.51% of price
Prior day high
1.20
PDH
Prior day low
1.12
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 212.63K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-12.10%
-14.0%
1M
+32.60%
+31.4%
3M
+36.25%
+31.7%
6M
+57.97%
+39.8%
YTD
-7.63%
-21.9%
1Y
-30.13%
-46.5%
3Y
-86.37%
-168.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TELA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.19M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | CAPPER JOSEPH H Director |
BUY | 75.00K | $78.44K | Direct |
| Aug 17, 26 | GETZ HEATHER C Chief Executive Officer |
BUY | 12.50K | $8.31K | Direct |
| Aug 14, 26 | GETZ HEATHER C Chief Executive Officer |
BUY | 15.00K | $10.47K | Direct |
| Aug 3, 26 | GETZ HEATHER C Chief Executive Officer |
STOCK | 500.00K | $0 | Direct |
| Jul 15, 26 | CAPPER JOSEPH H Director |
STOCK | 6.23K | $4.89K | Direct |
| Jul 15, 26 | PLOVANIC WILLIAM J. Director |
STOCK | 20.93K | $16.43K | Direct |
| Jun 9, 26 | NOHRA GUY P Director |
STOCK | 23.60K | $0 | Direct |
| Jun 9, 26 | THOMAS PAUL G Director |
STOCK | 23.60K | $0 | Direct |
| Jun 9, 26 | NEELS GUIDO J Director |
STOCK | 23.60K | $0 | Direct |
| Jun 9, 26 | CAPPER JOSEPH H Director |
STOCK | 23.60K | $0 | Direct |
| Jun 9, 26 | PLOVANIC WILLIAM J. Director |
STOCK | 11.68K | $0 | Direct |
| Jun 9, 26 | ROCCHIO BETTY JO Director |
STOCK | 11.68K | $0 | Direct |
| Feb 20, 26 | KOBLISH ANTONY Chief Executive Officer |
STOCK | 176.00K | $0 | Direct |
| Feb 20, 26 | CUCA ROBERTO Chief Operating Officer |
STOCK | 57.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BLIZARD JEFFREY |
President | 205.13K | Stock Award(Grant) |
CAPPER JOSEPH H |
Director | 104.83K | Purchase |
CUCA ROBERTO |
Chief Operating Officer | 257.38K | Stock Award(Grant) |
EW HEALTHCARE PARTNERS FUND 2, L.P. |
Beneficial Owner of more than 10% of a Class of Security | 7.71M | Purchase |
FIRESTONE GREGORY A |
Officer | 139.31K | Stock Award(Grant) |
GETZ HEATHER C |
Chief Executive Officer | 532.50K | Purchase |
KOBLISH ANTONY |
Chief Executive Officer | 586.21K | Stock Award(Grant) |
PLOVANIC WILLIAM J. |
Director | 44.53K | Stock Award(Grant) |
SMEYKAL MEGAN |
Officer | 66.87K | Stock Award(Grant) |
TALMO PAUL |
Chief Technology Officer | 173.44K | Stock Award(Grant) |
Fundamentals
Market cap$49.21M
Enterprise value$76.43M
Revenue (TTM)$79.91M
Gross profit$54.57M
EBITDA$-33.01M
Net income$-41.18M
EPS (TTM)$-0.77
Free cash flow$-17.71M
Total cash$30.42M
Total debt$57.92M
Book value / share$-0.35
Shares outstanding45.14M
Float21.23M
Short % of float1.76%
Dividend yield0.00%
Beta (5Y)1.36
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.42
PEG ratio—
Price / sales—
Price / book—
EV / revenue0.96
EV / EBITDA-2.32
Gross margin68.29%
Operating margin-48.12%
Profit margin-51.53%
Return on equity—
Return on assets-33.40%
Debt / equity—
Current ratio2.99
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $80.28M | $69.30M | $58.45M | $41.42M | +15.8% |
| Operating revenue | $80.28M | $69.30M | $58.45M | $41.42M | +15.8% |
| Cost of revenue | $25.93M | $22.81M | $18.34M | $14.37M | +13.7% |
| Gross profit | $54.34M | $46.49M | $40.11M | $27.04M | +16.9% |
| Research & development | $9.22M | $8.81M | $9.62M | $8.94M | +4.6% |
| Selling, general & admin | $78.88M | $79.37M | $74.57M | $57.11M | -0.6% |
| Total operating expense | $88.10M | $88.18M | $84.19M | $66.05M | -0.1% |
| Operating income | -$33.76M | -$41.70M | -$44.08M | -$39.01M | +19.0% |
| Net interest income | -$5.25M | -$5.29M | -$5.22M | -$4.05M | +0.9% |
| Pre-tax income | -$38.60M | -$37.98M | -$46.66M | -$44.30M | -1.6% |
| Tax provision | $230.00K | -$144.00K | $0 | $0 | +259.7% |
| Net income | -$38.83M | -$37.84M | -$46.66M | -$44.30M | -2.6% |
| Net income to common | -$38.83M | -$37.84M | -$46.66M | -$44.30M | -2.6% |
| Basic EPS | -0.83 | -1.33 | -2.04 | -2.72 | +37.6% |
| Diluted EPS | -0.83 | -1.33 | -2.04 | -2.72 | +37.6% |
| EBIT | -$33.36M | -$32.70M | -$41.44M | -$40.24M | -2.0% |
| EBITDA | -$32.35M | -$31.68M | -$40.63M | -$39.06M | -2.1% |
| Basic shares | 46.95M | 28.53M | 22.87M | 16.27M | +64.6% |
| Diluted shares | 46.95M | 28.53M | 22.87M | 16.27M | +64.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $50.84M | $52.67M | $46.73M | $42.02M | -3.5% |
| Cash & short-term investments | $50.84M | $52.67M | $46.73M | $42.02M | -3.5% |
| Accounts receivable | $10.35M | $10.10M | $9.74M | $6.62M | +2.5% |
| Inventory | $11.02M | $12.78M | $13.16M | $11.79M | -13.8% |
| Total current assets | $75.58M | $78.07M | $71.73M | $62.45M | -3.2% |
| Property, plant & equipment | $3.73M | $4.08M | $3.94M | $2.91M | -8.6% |
| Goodwill & intangibles | $1.36M | $1.74M | $2.12M | $2.50M | -21.9% |
| Total assets | $81.42M | $86.57M | $78.05M | $67.86M | -6.0% |
| Total current liabilities | $17.98M | $15.60M | $16.97M | $12.40M | +15.2% |
| Long-term debt | $55.65M | $41.12M | $40.52M | $39.92M | +35.3% |
| Total debt | $56.18M | $41.67M | $41.08M | $40.26M | +34.8% |
| Total liabilities | $75.11M | $58.11M | $59.17M | $53.55M | +29.2% |
| Retained earnings | -$397.56M | -$358.73M | -$320.89M | -$274.23M | -10.8% |
| Shareholder equity | $6.31M | $28.46M | $18.88M | $14.30M | -77.8% |
| Working capital | $57.61M | $62.47M | $54.76M | $50.04M | -7.8% |
| Net tangible assets | $4.95M | $26.72M | $16.76M | $11.81M | -81.5% |
| Shares issued | 44.54M | 39.40M | 24.49M | 19.17M | +13.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$38.83M | -$37.84M | -$46.66M | -$44.30M | -2.6% |
| Depreciation & amortisation | $1.01M | $1.01M | $808.00K | $1.19M | -0.2% |
| Stock-based compensation | $3.80M | $4.36M | $5.03M | $3.99M | -13.0% |
| Change in working capital | $1.42M | -$4.83M | -$1.67M | -$5.76M | +129.4% |
| Operating cash flow | -$28.22M | -$41.59M | -$40.86M | -$40.75M | +32.2% |
| Capital expenditure | -$448.00K | -$989.00K | -$611.00K | -$1.87M | +54.7% |
| Investing cash flow | $846.00K | $4.45M | -$599.00K | -$1.87M | -81.0% |
| Financing cash flow | $25.75M | $43.06M | $46.27M | $40.85M | -40.2% |
| Free cash flow | -$28.67M | -$42.58M | -$41.47M | -$42.62M | +32.7% |
| End cash position | $51.09M | $52.94M | $46.99M | $42.02M | -3.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $19.29M | $19.06M | $20.87M | $20.69M | $20.20M | +1.2% |
| Operating revenue | $19.29M | $19.06M | $20.87M | $20.69M | $20.20M | +1.2% |
| Cost of revenue | $5.35M | $6.54M | $7.11M | $6.72M | $6.09M | -18.2% |
| Gross profit | $13.94M | $12.52M | $13.76M | $13.97M | $14.11M | +11.4% |
| Research & development | $2.72M | $2.34M | $2.13M | $2.35M | $2.20M | +16.2% |
| Selling, general & admin | $20.50M | $20.70M | $18.27M | $19.18M | $20.98M | -1.0% |
| Total operating expense | $23.23M | $23.05M | $20.40M | $21.52M | $23.19M | +0.8% |
| Operating income | -$9.28M | -$10.53M | -$6.65M | -$7.55M | -$9.08M | +11.8% |
| Net interest income | -$2.08M | -$2.05M | -$1.64M | -$1.20M | -$1.19M | -1.1% |
| Pre-tax income | -$11.20M | -$12.21M | -$8.90M | -$8.60M | -$9.89M | +8.3% |
| Tax provision | $60.00K | $60.00K | $145.00K | $0 | $33.00K | 0.0% |
| Net income | -$11.26M | -$12.27M | -$9.04M | -$8.60M | -$9.92M | +8.2% |
| Net income to common | -$11.26M | -$12.27M | -$9.04M | -$8.60M | -$9.92M | +8.2% |
| Basic EPS | -0.20 | -0.21 | -0.17 | -0.19 | -0.22 | +4.8% |
| Diluted EPS | -0.20 | -0.21 | -0.17 | -0.19 | -0.22 | +4.8% |
| EBIT | -$9.13M | -$10.16M | -$7.26M | -$7.40M | -$8.70M | +10.2% |
| EBITDA | -$8.86M | -$9.90M | -$7.03M | -$7.15M | -$8.43M | +10.5% |
| Basic shares | 57.41M | 57.26M | 51.68M | 45.42M | 45.37M | +0.3% |
| Diluted shares | 57.41M | 57.26M | 51.68M | 45.42M | 45.37M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $30.42M | $39.54M | $50.84M | $29.71M | $34.98M | -23.1% |
| Cash & short-term investments | $30.42M | $39.54M | $50.84M | $29.71M | $34.98M | -23.1% |
| Accounts receivable | $9.64M | $9.71M | $10.35M | $11.27M | $11.24M | -0.8% |
| Inventory | $11.06M | $12.21M | $11.02M | $11.56M | $11.37M | -9.4% |
| Total current assets | $54.49M | $64.30M | $75.58M | $56.05M | $60.74M | -15.3% |
| Property, plant & equipment | $3.43M | $3.60M | $3.73M | $3.77M | $3.78M | -4.8% |
| Goodwill & intangibles | $1.17M | $1.26M | $1.36M | $1.45M | $1.55M | -7.5% |
| Total assets | $59.74M | $69.89M | $81.42M | $61.59M | $67.54M | -14.5% |
| Total current liabilities | $18.22M | $17.83M | $17.98M | $16.98M | $19.06M | +2.2% |
| Current debt | — | — | — | — | $3.33M | — |
| Long-term debt | $56.08M | $55.87M | $55.65M | $41.49M | $38.05M | +0.4% |
| Total debt | $56.61M | $56.39M | $56.18M | $42.02M | $41.90M | +0.4% |
| Total liabilities | $75.60M | $75.09M | $75.11M | $60.03M | $58.35M | +0.7% |
| Retained earnings | -$421.10M | -$409.83M | -$397.56M | -$388.52M | -$379.92M | -2.7% |
| Shareholder equity | -$15.87M | -$5.20M | $6.31M | $1.56M | $9.18M | -205.1% |
| Working capital | $36.27M | $46.47M | $57.61M | $39.07M | $41.68M | -21.9% |
| Net tangible assets | -$17.04M | -$6.46M | $4.95M | $103.00K | $7.63M | -163.5% |
| Shares issued | 44.83M | 44.77M | 44.54M | 40.34M | 39.58M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$11.26M | -$12.27M | -$9.04M | -$8.60M | -$9.92M | +8.2% |
| Depreciation & amortisation | $266.00K | $264.00K | $225.00K | $248.00K | $270.00K | +0.8% |
| Stock-based compensation | $613.00K | $816.00K | $812.00K | $955.00K | $985.00K | -24.9% |
| Change in working capital | $426.00K | -$1.21M | $1.10M | $529.00K | $367.00K | +135.3% |
| Operating cash flow | -$9.38M | -$11.17M | -$4.87M | -$5.72M | -$7.91M | +16.0% |
| Capital expenditure | -$59.00K | -$119.00K | -$91.00K | -$211.00K | -$114.00K | +50.4% |
| Investing cash flow | $239.00K | $190.00K | $192.00K | $312.00K | $204.00K | +25.8% |
| Financing cash flow | -$15.00K | -$298.00K | $25.84M | $24.00K | -$3.00K | +95.0% |
| Free cash flow | -$9.44M | -$11.29M | -$4.96M | -$5.93M | -$8.02M | +16.4% |
| End cash position | $30.62M | $39.79M | $51.09M | $29.96M | $35.24M | -23.0% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
+129.4% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
1
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.18 | -0.20 | -12.4% |
| Mar 2026 | -0.19 | — | — |
| Dec 2025 | -0.18 | -0.17 | +6.6% |
| Sep 2025 | -0.20 | -0.19 | +5.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.16 | 6 | $20.03M | -3.2% |
| Next quarter | -0.12 | 6 | $21.20M | +1.6% |
| Current year | -0.69 | 6 | $79.59M | -0.9% |
| Next year | -0.45 | 6 | $86.94M | +9.2% |
Analyst targets & ownership
Mean target$2.08
High target$3.00
Low target$1.00
Implied upside79.60%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy1 / 4
Hold1
Sell / Strong sell0 / 0
Held by insiders7.11%
Held by institutions63.29%
Institutions holding50
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.21
-3.89% from price
SMA 20
1.17
-6.90% from price
SMA 50
0.91
+19.54% from price
SMA 100
0.87
+33.74% from price
SMA 200
0.87
+25.87% from price
EMA 12
1.17
-0.74% from price
EMA 26
1.09
+6.31% from price
EMA 50
0.99
+17.23% from price
RSI (14)
50.3
Neutral
MACD (12,26,9)
0.08
Hist -0.03
ATR (14)
0.13
12.25% of price
Realised vol 30D
89.1%
Annualised
Bollinger upper
1.44
20, 2σ
Bollinger lower
0.90
20, 2σ
50 / 200 cross
Golden
0.91 vs 0.87
Trend bias
Above 200
+25.87%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.82
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
89.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-64.3%
Peak to trough
Max drawdown 5Y
-95.9%
Peak to trough
ATR 14
0.13
12.25% of price
Beta (reported)
1.36
5Y monthly, from filing
Short interest
Shares short
550.82K
Prior 338.49K
Change vs prior
+62.7%
Shorts adding
% of float
1.76%
Normal
% of shares out
1.22%
Against total outstanding
Days to cover
1.8
Liquid
Float
21.23M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 26 | Craig-Hallum | INITIATED | — | Buy |
| Mar 27, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Mar 25, 26 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Mar 25, 26 | Lake Street | MAINTAINED | Buy | Buy |
| Mar 25, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Dec 1, 25 | Lake Street | MAINTAINED | Buy | Buy |
| Nov 18, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Nov 14, 25 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Nov 14, 25 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Mar 21, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Mar 21, 25 | Citizens Capital Markets | MAINTAINED | Market Outperform | Market Outperform |
| Mar 21, 25 | Piper Sandler | DOWNGRADE | Overweight | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-06
Corporate Changes & Voting Matters
8-K · 2026-10-05
Corporate Changes & Voting Matters
8-K · 2026-09-29
Corporate Changes & Voting Matters
8-K · 2026-09-18
Proxy Statements
DEF 14A · 2026-09-14
Proxy Statements
PRE 14A · 2026-09-04
Corporate Changes & Voting Matters
8-K · 2026-08-31
Corporate Changes & Voting Matters
8-K/A · 2026-08-13
Headlines
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
GlobeNewswire · 2d ago
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
GlobeNewswire · 37d ago
TELA Bio (TELA) Q2 2026 Earnings Call Transcript
Motley Fool · 49d ago
TELA Bio Inc (TELA) (Q2 2026) Earnings Call Highlights: Navigating PRS Headwinds and Strategic ...
GuruFocus.com · 57d ago
TELA Bio, Inc. Q2 2026 Earnings Call Summary
Moby · 57d ago
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 58d ago
TELA Bio Reports Second Quarter 2026 Financial Results
GlobeNewswire · 58d ago
Earnings To Watch: TELA Bio Inc (TELA) Q2 2026 -- GF Value Sees 97% Upside
GuruFocus.com · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.